Darpp-32 and its truncated variant t-Darpp have antagonistic effects on breast cancer cell growth and Herceptin resistance

PLoS ONE

Volumn 4, Issue 7, 2009, Pages

  Gu, Long ^a   Waliany, Sarah ^a   Kane, Susan E ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOPROTEIN DARPP 32; PHOSPHOPROTEIN PHOSPHATASE INHIBITOR; PROTEIN KINASE B; TRASTUZUMAB; ANTINEOPLASTIC AGENT; ISOPROTEIN; MONOCLONAL ANTIBODY; PPP1R1B PROTEIN, HUMAN;

AMINO TERMINAL SEQUENCE; ARTICLE; BINDING AFFINITY; BREAST CANCER; CANCER GROWTH; CANCER INHIBITION; CANCER RESISTANCE; CONTROLLED STUDY; DNA BINDING; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; BREAST TUMOR; DRUG RESISTANCE; FEMALE; GEL MOBILITY SHIFT ASSAY; GENETICS; PATHOLOGY; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; DOPAMINE AND CAMP-REGULATED PHOSPHOPROTEIN 32; DRUG RESISTANCE, NEOPLASM; ELECTROPHORETIC MOBILITY SHIFT ASSAY; FEMALE; HUMANS; PROTEIN ISOFORMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 67650667730     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0006220     Document Type: Article

References (35)

1. Hung MC, Lau YK (1999) Basic science of HER-2/neu: a review. Semin Oncol 26: 51-59.
2. Adams GP, Weiner LM (2005) Monoclonal antibody therapy of cancer. Nat Biotechnol 23: 1147-1157.
3. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, et al. (1999) Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17: 2639-2648.
4. Esteva FJ, Valero V, Booser D, Guerra LT, Murray JL, et al. (2002) Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 20: 1800-1808.
5. Seidman AD, Fornier MN, Esteva FJ, Tan L, Kaptain S, et al. (2001) Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 19: 2587-2595.
6. Slamon DJ, Leyland-Jones B, Shak S, H. F, Paton V, et al. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783-792.
7. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, et al. (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20: 719-726.
8. Chan CT, Metz MZ, Kane SE (2005) Differential sensitivities of trastuzumab (Herceptin)-resistant human breast cancer cells to phosphoinositide-3 kinase (PI-3K) and epidermal growth factor receptor (EGFR) kinase inhibitors. Breast Cancer Res Treat 91: 187-201.
9. Nahta R, Esteva FJ (2006) Herceptin: mechanisms of action and resistance. Cancer Lett 232: 123-138.
10. Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S, et al. (2002) Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Research 62: 4132-4141.
11. Yuan TL, Cantley LC (2008) PI3K pathway alterations and cancer: variations on a theme. Oncogene 27: 5497-5510.
12. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, et al. (2004) High frequency of mutations of the PIK3CA gene in human cancers. Science 304: 554.
13. Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, et al. (2007) A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12: 395-402.
14. Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, et al. (2004) PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6: 117-127.
15. Fujita T, Doihara H, Kawasaki K, Takabatake D, Takahashi H, et al. (2006) PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer. Br J Cancer 94: 247-252.
16. Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M (2001) Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 93: 1852-1857.
17. Shattuck DL, Miller JK, Carraway III KL, Sweeney C (2008) Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells. Cancer Research 68: 1471-1477.
18. Miller KD (2004) The role of ErbB inhibitors in trastuzumab resistance. The Oncologist 9 (suppl3): 16-19.
19. Ritter CA, Perez-Torres M, Rinehart C, Guix M, Dugger T, et al. (2007) Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network. Clin Cancer Res 13: 4909-4919.
20. Stern DF (2008) ErbB3/Her3 and ErbB2/Her2 duet in mammary development and breast cancer. J Mammary Gland Biol Neoplasia 13: 215-223.
21. Brognard J, Newton AC (2008) PHLiPPing the switch on Akt and protein kinase C signaling. Trends Endocrinol Metab 19: 223-230.
22. Xu W, Yuan X, Jung YJ, Yang Y, Basso A, et al. (2003) The heat shock protein 90 inhibitor geldanamycin and the ErbB inhibitor ZD1839 promote rapid PP1 phosphatase-dependent inactivation of Akt in ErbB2 overexpressing breast cancer cells. Cancer Research 63: 7777-7784.
23. Ceulemans H, Bollen M (2003) Functional diversity of protein phosphatase-1, a cellular economizer and reset button. Physiol Rev 84: 1-39.
24. kip1 down-regulation is associated with trastuzumab resistance in breast cancer cells. Cancer Research 64: 3981-3986.
25. 2-terminal kinase, phosphoinositide 3-kinase, and p70 S6 kinase pathways in regulation of cyclin G2 expression in human breast cancer cells. Mol Cancer Ther 6: 2843-2857.
26. Giuliani R, Durbecq V, Di Leo A, Paesmans M, Larsimont D, et al. (2007) Phosphorylated HER-2 tyrosine kinase and Her-2/neu gene amplification as predictive factors of response to trastuzumab in patients with HER-2 overexpressing metastatic breast cancer (MBC). Eur J Cancer 43: 725-735.
27. Collins SP, Uhlerm MD (1997) Characterization of PKIgamma, a novel isoform of the protein kinase inhibitor of cAMP-dependent protein kinase. J Biol Chem 272: 18169-18178.
28. Brady MJ, Printen JA, Mastick CC, Saltiel AR (1997) Role of protein targeting to glycogen (PTG) in the regulation of protein phosphatase-1 activity. J Biol Chem 272: 20198-20204.
29. Svenningsson P, Nishi A, Fisone G, Girault JA, Nairn AC, et al. (2004) DARPP-32: an integrator of neurotransmission. Annu Rev Pharmacol Toxicol 44: 269-296.
30. Beckler A, Moskaluk CA, Zaika A, Hampton GM, Powell SM, et al. (2003) Overexpression of the 32-kilodalton dopamine and cyclic adenosine 3′,5′-monophosphate-regulated phosphoprotein in common adenocarcinomas. Cancer 98: 1547-1551.
31. Belkhiri A, Dar AA, Peng DF, Razvi MH, Rinehart C, et al. (2008) Expression of t-DARPP mediates trastuzumab resistance in breast cancer cells. Clin Cancer Res 14: 4564-4571.
32. Belkhiri A, Dar AA, Zaika A, Kelley M, El-Rifai W (2008) t-Darpp promotes cancer cell survival by up-regulation of bcl2 through Akt-dependent mechanism. Cancer Research 68: 395-403.
33. Belkhiri A, Zaika A, Pidkovka N, Knuutila S, Moskaluk C, et al. (2005) Darpp-32: a novel antiapoptotic gene in upper gastrointestinal carcinomas. Cancer Research 65: 6583-6592.
34. El-Rifai W, Smith MFJ, Li GM, Beckler A, Carl VS, et al. (2002) Gastric cancers overexpress DARPP-32 and a novel isoform, t-DARPP. Cancer Research 62: 4061-4064.
35. Hamel S, Bouchard A, Ferrario C, Hassan S, Aguilar-Mahecha A, et al. (2009) Both t-Darpp and DARPP-32 can cause resistance to trastuzumab in breast cancer cells and are frequently expressed in primary breast cancers. Breast Cancer Res Treat.